Benzinga Esperion Acquires Enbumyst Maker Corstasis
Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst. Importance Rank: 1 read more
Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst. Importance Rank: 1 read more